Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 557

1.

Stimulus Sensitive Foot Myoclonus: A Clue to Coeliac Disease.

Jesús S, Latorre A, Vinuela A, Fahn S, Bhatia KP, Balint B.

Mov Disord Clin Pract. 2019 Apr 4;6(4):320-323. doi: 10.1002/mdc3.12753. eCollection 2019 Apr.

PMID:
31061841
2.

SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease.

Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, Ruskey JA, Leblond CS, Ambalavanan A, Laurent SB, Spiegelman D, Dionne-Laporte A, Liong C, Levy OA, Fahn S, Waters C, Kuo SH, Chung WK, Ford B, Marder KS, Kang UJ, Hassin-Baer S, Greenbaum L, Trempe JF, Wolf P, Oliva P, Zhang XK, Clark LN, Langlois M, Dion PA, Fon EA, Dupre N, Rouleau GA, Gan-Or Z.

Mov Disord. 2019 Apr;34(4):526-535. doi: 10.1002/mds.27642. Epub 2019 Feb 20.

PMID:
30788890
3.

Video Review of Baseline Performance on Global Ratings in a Double-Blind Placebo Surgery Trial.

McRae C, Caspari J, Russell D, Ellgring H, Bezzant C, Greene P, Fahn S.

Mov Disord Clin Pract. 2018 Oct 4;5(6):597-602. doi: 10.1002/mdc3.12666. eCollection 2018 Nov-Dec.

PMID:
30637279
4.

A novel exaggerated "spino-bulbo-spinal like" reflex of lower brainstem origin.

Merchant SH, Vial F, Leodori G, Fahn S, Pullman SL, Hallett M.

Parkinsonism Relat Disord. 2019 Apr;61:34-38. doi: 10.1016/j.parkreldis.2018.10.007. Epub 2018 Oct 6.

PMID:
30316728
5.

Common and rare GCH1 variants are associated with Parkinson's disease.

Rudakou U, Ouled Amar Bencheikh B, Ruskey JA, Krohn L, Laurent SB, Spiegelman D, Liong C, Fahn S, Waters C, Monchi O, Fon EA, Dauvilliers Y, Alcalay RN, Dupré N, Gan-Or Z.

Neurobiol Aging. 2019 Jan;73:231.e1-231.e6. doi: 10.1016/j.neurobiolaging.2018.09.008. Epub 2018 Sep 15.

PMID:
30314816
6.

Hoehn and Yahr stage 3 and postural stability item in the movement disorder society-unified Parkinson's disease rating scale.

Gupta DK, Fahn S, Tatsuoka C, Kang UJ.

Mov Disord. 2018 Jul;33(7):1188-1189. doi: 10.1002/mds.27453. No abstract available.

PMID:
30153396
7.

Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation.

Shah H, Liong C, Levy OA, Waters C, Fahn S, Marder K, Kang UJ, Wolf P, Oliva P, Zhang K, Alcalay RN, Gutierrez J.

Stroke. 2018 Aug;49(8):1977-1980. doi: 10.1161/STROKEAHA.118.021964.

8.

Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease.

Ruskey JA, Greenbaum L, Roncière L, Alam A, Spiegelman D, Liong C, Levy OA, Waters C, Fahn S, Marder KS, Chung W, Yahalom G, Israeli-Korn S, Livneh V, Fay-Karmon T, Alcalay RN, Hassin-Baer S, Gan-Or Z.

Eur J Med Genet. 2019 Jan;62(1):65-69. doi: 10.1016/j.ejmg.2018.05.005. Epub 2018 May 26.

PMID:
29842932
9.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R.

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

10.

Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease.

Sulzer D, Cassidy C, Horga G, Kang UJ, Fahn S, Casella L, Pezzoli G, Langley J, Hu XP, Zucca FA, Isaias IU, Zecca L.

NPJ Parkinsons Dis. 2018 Apr 10;4:11. doi: 10.1038/s41531-018-0047-3. eCollection 2018. Review.

11.

Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort.

Kim R, Lee J, Kim Y, Kim A, Jang M, Kim HJ, Jeon B, Kang UJ, Fahn S.

Parkinsonism Relat Disord. 2018 Jun;51:49-54. doi: 10.1016/j.parkreldis.2018.02.047. Epub 2018 Feb 28.

PMID:
29523394
12.

Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.

Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S.

J Neurol Sci. 2018 Jun 15;389:67-75. doi: 10.1016/j.jns.2018.02.010. Epub 2018 Feb 5.

PMID:
29454493
13.

The nosology of tardive syndromes.

Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA.

J Neurol Sci. 2018 Jun 15;389:10-16. doi: 10.1016/j.jns.2018.02.008. Epub 2018 Feb 6.

PMID:
29433810
14.

Alpha galactosidase A activity in Parkinson's disease.

Alcalay RN, Wolf P, Levy OA, Kang UJ, Waters C, Fahn S, Ford B, Kuo SH, Vanegas N, Shah H, Liong C, Narayan S, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK, Oliva P, Keutzer J, Marder K, Zhang XK.

Neurobiol Dis. 2018 Apr;112:85-90. doi: 10.1016/j.nbd.2018.01.012. Epub 2018 Feb 2.

15.

Two-hundred Years Later: Is Parkinson's Disease a Single Defined Entity?

Rodríguez-Violante M, Cervantes-Arriaga A, Fahn S, Tolosa E.

Rev Invest Clin. 2017 Nov-Dec;69(6):308-313. doi: 10.24875/RIC.17002291. Review.

16.

Adaptation of Stability during Perturbed Walking in Parkinson's Disease.

Martelli D, Luo L, Kang J, Kang UJ, Fahn S, Agrawal SK.

Sci Rep. 2017 Dec 19;7(1):17875. doi: 10.1038/s41598-017-18075-6.

17.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

18.

The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future.

Fahn S.

Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S1-S5. doi: 10.1016/j.parkreldis.2017.07.020. Epub 2017 Aug 1. Review.

PMID:
28784297
19.

Personal reflections about Lewis P. (Bud) Rowland (1925-2017).

Fahn S.

Neurology. 2017 May 30;88(22):2078-2079. doi: 10.1212/WNL.0000000000004050. No abstract available.

PMID:
28554897
20.

Inpatient treatment for functional neurologic disorders.

Williams DT, Lafaver K, Carson A, Fahn S.

Handb Clin Neurol. 2016;139:631-641. doi: 10.1016/B978-0-12-801772-2.00051-5. Review.

PMID:
27719878
21.

"Complex" dystonia is not a category in the new 2013 consensus classification.

Albanese A, Bhatia K, DeLong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Mink JW, Teller JK.

Mov Disord. 2016 Nov;31(11):1758-1759. doi: 10.1002/mds.26764. Epub 2016 Sep 10. No abstract available.

22.

Basal Ganglia Gliosis in a Case of Rapid-Onset Dystonia-Parkinsonism (DYT12) with a Novel Mutation in ATPase 1A3 (ATP1A3).

Sampson JB, Michaeli TH, Wright BA, Goldman JE, Vonsattel JP, Fahn S.

Mov Disord Clin Pract. 2016 May 19;3(6):618-620. doi: 10.1002/mdc3.12354. eCollection 2016 Nov-Dec. No abstract available.

23.

SCARB2 variants and glucocerebrosidase activity in Parkinson's disease.

Alcalay RN, Levy OA, Wolf P, Oliva P, Zhang XK, Waters CH, Fahn S, Kang U, Liong C, Ford B, Mazzoni P, Kuo S, Johnson A, Xiong L, Rouleau GA, Chung W, Marder KS, Gan-Or Z.

NPJ Parkinsons Dis. 2016;2. pii: 16004. Epub 2016 Mar 10.

24.

Oliver Sacks, MD, 1933-2015.

Fahn S.

Mov Disord. 2016 Apr;31(4):493-6. doi: 10.1002/mds.26602. No abstract available.

PMID:
27079682
25.

Levodopa therapy for Parkinson disease: A look backward and forward.

LeWitt PA, Fahn S.

Neurology. 2016 Apr 5;86(14 Suppl 1):S3-12. doi: 10.1212/WNL.0000000000002509. Epub 2016 Apr 4. Review.

PMID:
27044648
26.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
27.

Closing the tau loop: the missing tau mutation.

McCarthy A, Lonergan R, Olszewska DA, O'Dowd S, Cummins G, Magennis B, Fallon EM, Pender N, Huey ED, Cosentino S, O'Rourke K, Kelly BD, O'Connell M, Delon I, Farrell M, Spillantini MG, Rowland LP, Fahn S, Craig P, Hutton M, Lynch T.

Brain. 2015 Oct;138(Pt 10):3100-9. doi: 10.1093/brain/awv234. Epub 2015 Aug 21.

28.

Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease.

Virmani T, Moskowitz CB, Vonsattel JP, Fahn S.

Mov Disord. 2015 Dec;30(14):1874-84. doi: 10.1002/mds.26346. Epub 2015 Aug 3.

PMID:
26234730
29.

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.

Robakis D, Fahn S.

CNS Drugs. 2015 Jun;29(6):433-41. doi: 10.1007/s40263-015-0249-8. Review.

PMID:
26164425
30.

Essential Tips for Videotaping a Movement Disorders Patient Encounter.

Robakis D, Fahn S, Kestenbaum M.

Mov Disord Clin Pract. 2015 Jun 30;2(4):365-368. doi: 10.1002/mdc3.12204. eCollection 2015 Dec. No abstract available.

31.

Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, Mazzoni P, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK, Wolf P, Oliva P, Keutzer J, Marder K, Zhang X.

Brain. 2015 Sep;138(Pt 9):2648-58. doi: 10.1093/brain/awv179. Epub 2015 Jun 27.

32.

Masaya Segawa, MD, PhD, 1936-2014.

Nomura Y, Fahn S.

Mov Disord. 2015 Jun;30(7):883-5. doi: 10.1002/mds.26257. Epub 2015 May 23. No abstract available.

PMID:
26009805
33.

Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center.

Xie T, Kang UJ, Kuo SH, Poulopoulos M, Greene P, Fahn S.

NPJ Parkinsons Dis. 2015 May 21;1:15007. doi: 10.1038/npjparkd.2015.7. eCollection 2015.

34.

Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease.

Clark LN, Chan R, Cheng R, Liu X, Park N, Parmalee N, Kisselev S, Cortes E, Torres PA, Pastores GM, Vonsattel JP, Alcalay R, Marder K, Honig LL, Fahn S, Mayeux R, Shelanski M, Di Paolo G, Lee JH.

PLoS One. 2015 May 1;10(5):e0125204. doi: 10.1371/journal.pone.0125204. eCollection 2015.

35.

Introducing a new journal on Parkinson's disease.

Sulzer D, Chaudhuri KR, Fahn S.

NPJ Parkinsons Dis. 2015 Apr 22;1:15006. doi: 10.1038/npjparkd.2015.6. eCollection 2015. No abstract available.

36.

Reply: Oleh Hornykiewicz's contribution to the l-dopa story.

Fahn S.

Mov Disord. 2015 Jun;30(7):1008-9. doi: 10.1002/mds.26242. Epub 2015 Apr 16. No abstract available.

PMID:
25880230
37.

Erratum: Emerging topics in FXTAS.

Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe JA, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA.

J Neurodev Disord. 2015;7(1):13. doi: 10.1186/s11689-015-9108-7. Epub 2015 Apr 8.

38.

Genetic markers of Restless Legs Syndrome in Parkinson disease.

Gan-Or Z, Alcalay RN, Bar-Shira A, Leblond CS, Postuma RB, Ben-Shachar S, Waters C, Johnson A, Levy O, Mirelman A, Gana-Weisz M, Dupré N, Montplaisir J, Giladi N, Fahn S, Xiong L, Dion PA, Orr-Urtreger A, Rouleau GA.

Parkinsonism Relat Disord. 2015 Jun;21(6):582-5. doi: 10.1016/j.parkreldis.2015.03.010. Epub 2015 Mar 17.

39.

Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.

Kestenbaum M, Fahn S.

Expert Opin Drug Saf. 2015 May;14(5):761-7. doi: 10.1517/14740338.2015.1015986. Epub 2015 Feb 19. Review.

PMID:
25697185
40.

Emerging topics in FXTAS.

Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe J, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA.

J Neurodev Disord. 2014;6(1):31. doi: 10.1186/1866-1955-6-31. Epub 2014 Jul 30. Review. Erratum in: J Neurodev Disord. 2015;7(1):13.

41.

The medical treatment of Parkinson disease from James Parkinson to George Cotzias.

Fahn S.

Mov Disord. 2015 Jan;30(1):4-18. doi: 10.1002/mds.26102. Epub 2014 Dec 9. Review.

PMID:
25491387
42.

Levodopa: 50 years of a revolutionary drug for Parkinson disease.

Fahn S, Poewe W.

Mov Disord. 2015 Jan;30(1):1-3. doi: 10.1002/mds.26122. Epub 2014 Dec 8. No abstract available.

PMID:
25488146
43.

The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS.

Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065. Epub 2014 Nov 12.

44.

Reply to: psychogenic movement disorders: what's in a name?

Fahn S, Olanow CW.

Mov Disord. 2014 Nov;29(13):1699-701. doi: 10.1002/mds.26042. Epub 2014 Oct 12. No abstract available.

PMID:
25308926
45.

Mendelian randomization of serum urate and parkinson disease progression.

Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A; Parkinson Study Group.

Ann Neurol. 2014 Dec;76(6):862-8. doi: 10.1002/ana.24281. Epub 2014 Oct 3.

46.

Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.

Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L.

Neuropsychopharmacology. 2015 Feb;40(3):650-7. doi: 10.1038/npp.2014.214. Epub 2014 Sep 24.

47.

"Psychogenic movement disorders": they are what they are.

Fahn S, Olanow CW.

Mov Disord. 2014 Jun;29(7):853-6. doi: 10.1002/mds.25899. Epub 2014 May 5. No abstract available.

PMID:
24797587
48.

Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.

Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M, Nichols W, Rana HQ, Balwani M, Bier L, Elstein D, Zimran A.

JAMA Neurol. 2014 Jun;71(6):752-7. doi: 10.1001/jamaneurol.2014.313.

49.

Author response.

Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA.

Neurology. 2014 Feb 18;82(7):643. No abstract available.

PMID:
24745039
50.

Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease.

Arkadir D, Bergman H, Fahn S.

Neurology. 2014 Mar 25;82(12):1093-8. doi: 10.1212/WNL.0000000000000243.

PMID:
24663231

Supplemental Content

Support Center